284 related articles for article (PubMed ID: 34234755)
1. Immune Escape by Non-coding RNAs of the Epstein Barr Virus.
Münz C
Front Microbiol; 2021; 12():657387. PubMed ID: 34234755
[TBL] [Abstract][Full Text] [Related]
2. MicroRNAs of Epstein-Barr Virus Attenuate T-Cell-Mediated Immune Control
Murer A; Rühl J; Zbinden A; Capaul R; Hammerschmidt W; Chijioke O; Münz C
mBio; 2019 Jan; 10(1):. PubMed ID: 30647153
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr Virus Type 2 Infects T Cells and Induces B Cell Lymphomagenesis in Humanized Mice.
Coleman CB; Lang J; Sweet LA; Smith NA; Freed BM; Pan Z; Haverkos B; Pelanda R; Rochford R
J Virol; 2018 Nov; 92(21):. PubMed ID: 30089703
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity in Epstein Barr virus specific immune control.
Münz C
Curr Opin Virol; 2021 Feb; 46():1-8. PubMed ID: 32771660
[TBL] [Abstract][Full Text] [Related]
5. Modification of EBV Associated Lymphomagenesis and Its Immune Control by Co-Infections and Genetics in Humanized Mice.
Schuhmachers P; Münz C
Front Immunol; 2021; 12():640918. PubMed ID: 33833760
[TBL] [Abstract][Full Text] [Related]
6. Roles of Lytic Viral Replication and Co-Infections in the Oncogenesis and Immune Control of the Epstein-Barr Virus.
Deng Y; Münz C
Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34068598
[TBL] [Abstract][Full Text] [Related]
7. The Epstein-Barr Virus Oncogene EBNA1 Suppresses Natural Killer Cell Responses and Apoptosis Early after Infection of Peripheral B Cells.
Westhoff Smith D; Chakravorty A; Hayes M; Hammerschmidt W; Sugden B
mBio; 2021 Dec; 12(6):e0224321. PubMed ID: 34781735
[TBL] [Abstract][Full Text] [Related]
8. The BHLF1 Locus of Epstein-Barr Virus Contributes to Viral Latency and B-Cell Immortalization.
Yetming KD; Lupey-Green LN; Biryukov S; Hughes DJ; Marendy EM; Miranda JL; Sample JT
J Virol; 2020 Aug; 94(17):. PubMed ID: 32581094
[TBL] [Abstract][Full Text] [Related]
9. Multiple Viral microRNAs Regulate Interferon Release and Signaling Early during Infection with Epstein-Barr Virus.
Bouvet M; Voigt S; Tagawa T; Albanese M; Chen YA; Chen Y; Fachko DN; Pich D; Göbel C; Skalsky RL; Hammerschmidt W
mBio; 2021 Mar; 12(2):. PubMed ID: 33785626
[TBL] [Abstract][Full Text] [Related]
10. CD8+ T cells retain protective functions despite sustained inhibitory receptor expression during Epstein-Barr virus infection in vivo.
Chatterjee B; Deng Y; Holler A; Nunez N; Azzi T; Vanoaica LD; Müller A; Zdimerova H; Antsiferova O; Zbinden A; Capaul R; Dreyer JH; Nadal D; Becher B; Robinson MD; Stauss H; Münz C
PLoS Pathog; 2019 May; 15(5):e1007748. PubMed ID: 31145756
[TBL] [Abstract][Full Text] [Related]
11. Immune Evasion by Epstein-Barr Virus.
Ressing ME; van Gent M; Gram AM; Hooykaas MJ; Piersma SJ; Wiertz EJ
Curr Top Microbiol Immunol; 2015; 391():355-81. PubMed ID: 26428381
[TBL] [Abstract][Full Text] [Related]
12. EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors.
White RE; Rämer PC; Naresh KN; Meixlsperger S; Pinaud L; Rooney C; Savoldo B; Coutinho R; Bödör C; Gribben J; Ibrahim HA; Bower M; Nourse JP; Gandhi MK; Middeldorp J; Cader FZ; Murray P; Münz C; Allday MJ
J Clin Invest; 2012 Apr; 122(4):1487-502. PubMed ID: 22406538
[TBL] [Abstract][Full Text] [Related]
13. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.
Cui X; Snapper CM
Front Immunol; 2021; 12():734471. PubMed ID: 34691042
[TBL] [Abstract][Full Text] [Related]
14. Host Gene Expression Is Regulated by Two Types of Noncoding RNAs Transcribed from the Epstein-Barr Virus BamHI A Rightward Transcript Region.
Marquitz AR; Mathur A; Edwards RH; Raab-Traub N
J Virol; 2015 Nov; 89(22):11256-68. PubMed ID: 26311882
[TBL] [Abstract][Full Text] [Related]
15. Immune Control and Vaccination against the Epstein-Barr Virus in Humanized Mice.
Münz C
Vaccines (Basel); 2019 Dec; 7(4):. PubMed ID: 31861045
[TBL] [Abstract][Full Text] [Related]
16. Knockout of Epstein-Barr virus BPLF1 retards B-cell transformation and lymphoma formation in humanized mice.
Whitehurst CB; Li G; Montgomery SA; Montgomery ND; Su L; Pagano JS
mBio; 2015 Oct; 6(5):e01574-15. PubMed ID: 26489865
[TBL] [Abstract][Full Text] [Related]
17. CD4+ T cell responses in the immune control against latent infection by Epstein-Barr virus.
Paludan C; Münz C
Curr Mol Med; 2003 Jun; 3(4):341-7. PubMed ID: 12776989
[TBL] [Abstract][Full Text] [Related]
18. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.
Münz C; Bickham KL; Subklewe M; Tsang ML; Chahroudi A; Kurilla MG; Zhang D; O'Donnell M; Steinman RM
J Exp Med; 2000 May; 191(10):1649-60. PubMed ID: 10811859
[TBL] [Abstract][Full Text] [Related]
19. Galectin-9 Facilitates Epstein-Barr Virus Latent Infection and Lymphomagenesis in Human B Cells.
Xu JX; Zhang R; Huang DJ; Tang Y; Ping LQ; Huang BJ; Huang HQ; Busson P; Li J
Microbiol Spectr; 2023 Feb; 11(1):e0493222. PubMed ID: 36622166
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr Virus Genome Deletions in Epstein-Barr Virus-Positive T/NK Cell Lymphoproliferative Diseases.
Wongwiwat W; Fournier B; Bassano I; Bayoumy A; Elgueta Karstegl C; Styles C; Bridges R; Lenoir C; BoutBoul D; Moshous D; Neven B; Kanda T; Morgan RG; White RE; Latour S; Farrell PJ
J Virol; 2022 Jun; 96(12):e0039422. PubMed ID: 35612313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
